Xue-Di Zheng, Huan-Yu Li, Si-Yu Gao, Qi Wang, Jiang-Bo Liu
{"title":"低氧诱导因子-1α高表达与乳腺癌患者生存率降低相关：一项荟萃分析","authors":"Xue-Di Zheng, Huan-Yu Li, Si-Yu Gao, Qi Wang, Jiang-Bo Liu","doi":"10.5306/wjco.v16.i6.105691","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypoxia-inducible factor 1α (HIF-1α) plays a crucial role in the prognosis of breast cancer, but the current evidence remains inconclusive.</p><p><strong>Aim: </strong>To provide comprehensive evidence about the correlation of altered HIF-1α expression with overall survival (OS) and disease-free survival (DFS) in breast cancer patients.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Embase, and Web of Science databases to collect relevant articles that were published before April 8, 2024. A meta-analysis was used to assess the impact of altered HIF-1α expression on the OS and DFS of breast cancer patients. Subgroup and sensitivity analyses were also performed in this meta-analysis.</p><p><strong>Results: </strong>This meta-analysis included 40 studies. The average percentage of breast cancer patients with high HIF-1α expression was 39.6%. The overall meta-analysis results demonstrated that high HIF-1α expression is strongly linked to poor outcomes in patients of breast cancer. Compared with low HIF-1α expression, the overall hazard ratio for OS in patients with high HIF-1α expression was 1.47 [95% confidence interval (CI): 1.29-1.69], and the overall hazard ratio for DFS was 1.82 (95%CI: 1.56-2.12). Furthermore, both OS [1.18 (95%CI: 1.01-1.38)] and DFS [1.79 (95%CI: 1.03-3.11)] were markedly shorter in triple-negative breast cancer cases with high HIF-1α expression. Subgroup analysis revealed that the antibody used to detect HIF-1α expression affected only the correlation linking HIF-1α expression to DFS in breast cancer patients (<i>P</i> = 0.0004). Furthermore, the sensitivity analysis demonstrates that the overall conclusions of the meta-analysis were unaffected by the removal of individual studies.</p><p><strong>Conclusion: </strong>Compared to patients with low HIF-1α expression, those with high expression level had shorter OS and DFS. However, the prognostic significance of high HIF-1α expression varies across molecularly stratified breast cancer cohorts needs to be further elucidated.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"105691"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198862/pdf/","citationCount":"0","resultStr":"{\"title\":\"High hypoxia inducible factor-1α expression is associated with reduced survival in patients with breast cancer: A meta-analysis.\",\"authors\":\"Xue-Di Zheng, Huan-Yu Li, Si-Yu Gao, Qi Wang, Jiang-Bo Liu\",\"doi\":\"10.5306/wjco.v16.i6.105691\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hypoxia-inducible factor 1α (HIF-1α) plays a crucial role in the prognosis of breast cancer, but the current evidence remains inconclusive.</p><p><strong>Aim: </strong>To provide comprehensive evidence about the correlation of altered HIF-1α expression with overall survival (OS) and disease-free survival (DFS) in breast cancer patients.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Embase, and Web of Science databases to collect relevant articles that were published before April 8, 2024. A meta-analysis was used to assess the impact of altered HIF-1α expression on the OS and DFS of breast cancer patients. Subgroup and sensitivity analyses were also performed in this meta-analysis.</p><p><strong>Results: </strong>This meta-analysis included 40 studies. The average percentage of breast cancer patients with high HIF-1α expression was 39.6%. The overall meta-analysis results demonstrated that high HIF-1α expression is strongly linked to poor outcomes in patients of breast cancer. Compared with low HIF-1α expression, the overall hazard ratio for OS in patients with high HIF-1α expression was 1.47 [95% confidence interval (CI): 1.29-1.69], and the overall hazard ratio for DFS was 1.82 (95%CI: 1.56-2.12). Furthermore, both OS [1.18 (95%CI: 1.01-1.38)] and DFS [1.79 (95%CI: 1.03-3.11)] were markedly shorter in triple-negative breast cancer cases with high HIF-1α expression. Subgroup analysis revealed that the antibody used to detect HIF-1α expression affected only the correlation linking HIF-1α expression to DFS in breast cancer patients (<i>P</i> = 0.0004). Furthermore, the sensitivity analysis demonstrates that the overall conclusions of the meta-analysis were unaffected by the removal of individual studies.</p><p><strong>Conclusion: </strong>Compared to patients with low HIF-1α expression, those with high expression level had shorter OS and DFS. However, the prognostic significance of high HIF-1α expression varies across molecularly stratified breast cancer cohorts needs to be further elucidated.</p>\",\"PeriodicalId\":23802,\"journal\":{\"name\":\"World journal of clinical oncology\",\"volume\":\"16 6\",\"pages\":\"105691\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198862/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5306/wjco.v16.i6.105691\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i6.105691","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
High hypoxia inducible factor-1α expression is associated with reduced survival in patients with breast cancer: A meta-analysis.
Background: Hypoxia-inducible factor 1α (HIF-1α) plays a crucial role in the prognosis of breast cancer, but the current evidence remains inconclusive.
Aim: To provide comprehensive evidence about the correlation of altered HIF-1α expression with overall survival (OS) and disease-free survival (DFS) in breast cancer patients.
Methods: A systematic search was conducted in PubMed, Embase, and Web of Science databases to collect relevant articles that were published before April 8, 2024. A meta-analysis was used to assess the impact of altered HIF-1α expression on the OS and DFS of breast cancer patients. Subgroup and sensitivity analyses were also performed in this meta-analysis.
Results: This meta-analysis included 40 studies. The average percentage of breast cancer patients with high HIF-1α expression was 39.6%. The overall meta-analysis results demonstrated that high HIF-1α expression is strongly linked to poor outcomes in patients of breast cancer. Compared with low HIF-1α expression, the overall hazard ratio for OS in patients with high HIF-1α expression was 1.47 [95% confidence interval (CI): 1.29-1.69], and the overall hazard ratio for DFS was 1.82 (95%CI: 1.56-2.12). Furthermore, both OS [1.18 (95%CI: 1.01-1.38)] and DFS [1.79 (95%CI: 1.03-3.11)] were markedly shorter in triple-negative breast cancer cases with high HIF-1α expression. Subgroup analysis revealed that the antibody used to detect HIF-1α expression affected only the correlation linking HIF-1α expression to DFS in breast cancer patients (P = 0.0004). Furthermore, the sensitivity analysis demonstrates that the overall conclusions of the meta-analysis were unaffected by the removal of individual studies.
Conclusion: Compared to patients with low HIF-1α expression, those with high expression level had shorter OS and DFS. However, the prognostic significance of high HIF-1α expression varies across molecularly stratified breast cancer cohorts needs to be further elucidated.
期刊介绍：
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
